Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Cerulean Pharma Inc. to Convene Nanomedicine Pioneers at 2010 American Chemical Society (ACS) National Meeting & Exposition in Boston

Abstract:
ACS Symposium Will Examine Nanotechnology's Potential Impact on Developing Improved Therapies and Diagnostics to Address a Broad Range of Diseases

Cerulean Pharma Inc. to Convene Nanomedicine Pioneers at 2010 American Chemical Society (ACS) National Meeting & Exposition in Boston

Cambridge, MA | Posted on August 19th, 2010

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced it will assemble a group of leading scientific experts at the American Chemical Society's ("ACS") 240th National Meeting & Exposition for a three-day thought leadership summit on the advancement of nanotechnology in the pharmaceutical and diagnostic industries. ACS, which bills itself as the world's largest scientific society, will host its national meeting from August 22 through August 26 at the Boston Convention and Exhibition Center in Boston, Massachusetts.

The inaugural symposium, titled "Multifunctional Nanoparticles for Drug Delivery and Imaging," will feature close to 60 oral and poster presentations from renowned U.S. and international researchers. Key themes will include diagnostic imaging, experimental therapy, and drug delivery technologies for therapeutic agents ranging from small molecules and peptides, to new classes of therapies such as siRNA.

"Nanotechnology has the potential to revolutionize medicine by improving the safety, efficacy, and bioavailability of therapies," said Robert S. Langer, Ph.D., David H. Koch Institute Professor at the Massachusetts Institute of Technology and a keynote speaker at the nanotechnology summit. "An ACS National Meeting symposium, focused on the key role nanotechnology will play in the future of medicine, represents significant validation for this exciting research area."

Dr. Langer will deliver his keynote address on Sunday, August 22, highlighting the most promising potential applications of nanotechnology in medicine. A second keynote address will be delivered on Monday, August 23, by Piotr Grodzinski, Ph.D., Director of the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer, which will focus on the latest development in nanotechnology-based cancer therapy.

"ACS is a premier global scientific organization whose decision to highlight nanotechnology in medicine lends significant credibility to this emerging field," said Oliver Fetzer, Ph.D., President and Chief Executive Officer of Cerulean.

"We are excited to convene leading scientific experts who are shaping the future of this promising research area," added John Ryan, Ph.D., M.D., Cerulean's Chief Medical Officer. "Cerulean is committed to continuing its leadership position in nanopharmaceuticals by advancing its clinical and pre-clinical programs, and by creating opportunities for thought leaders to gather and discuss new discoveries and advances in the technology."

At the symposium, Dr. Ryan will be presenting data on CRLX101 (formerly IT-101), Cerulean's clinical nanopharmaceutical drug candidate in Phase 2a development. Company scientists will also be presenting data on CRLX288, one of Cerulean's pre-clinical development candidates, details of which will be revealed for the first time at this symposium.

Copies of Cerulean's oral and poster presentation abstracts are available at abstracts.acs.org/chem/240nm/program/divisionindex.php by searching the term "Cerulean"

####

About Cerulean Pharma
Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of nanopharmaceuticals optimized to make drugs more effective and with fewer side effects. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company's technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lux Capital, Bessemer Venture Partners, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Schwartz Communications
Andrew Law/Benjamin Navon
+1 781-684-0770

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Antibacterial Ceramic Nanoparticles, Appropriate Material for Medical Devices May 3rd, 2015

Oxford Instruments announces winners of the 2015 Sir Martin Wood Science Prize for China May 2nd, 2015

Time Dependant Spectroscopy of Microscopic Samples: CRAIC TimePro™ software is used with CRAIC Technologies microspectrometers to measure the kinetic UV-visible-NIR, Raman and fluorescence spectra of microscopic sample areas May 2nd, 2015

ORNL researchers probe chemistry, topography and mechanics with one instrument May 2nd, 2015

Possible Futures

Printing Silicon on Paper, with Lasers April 21st, 2015

A glass fiber that brings light to a standstill: By coupling photons to atoms, light in a glass fiber can be slowed down to the speed of an express train; for a short while it can even be brought to a complete stop April 9th, 2015

Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015

Nanotechnology Enabled Drug Delivery to Influence Future Diagnosis and Treatments of Diseases March 21st, 2015

Nanomedicine

Antibacterial Ceramic Nanoparticles, Appropriate Material for Medical Devices May 3rd, 2015

Polymeric Nanocarriers Improve Performance of Anticancer Drugs April 30th, 2015

Making robots more human April 29th, 2015

A phone with the ultimate macro feature: New attachment turns a smartphone into a microscope that can image and size DNA molecules 50,000 times thinner than a human hair April 29th, 2015

Announcements

Antibacterial Ceramic Nanoparticles, Appropriate Material for Medical Devices May 3rd, 2015

Nanometrics to Present at the B. Riley & Co. 16th Annual Investor Conference May 2nd, 2015

Time Dependant Spectroscopy of Microscopic Samples: CRAIC TimePro™ software is used with CRAIC Technologies microspectrometers to measure the kinetic UV-visible-NIR, Raman and fluorescence spectra of microscopic sample areas May 2nd, 2015

ORNL researchers probe chemistry, topography and mechanics with one instrument May 2nd, 2015

Events/Classes

Nanometrics to Present at the B. Riley & Co. 16th Annual Investor Conference May 2nd, 2015

No Hogwarts invitation required: Invisibility cloaks move into the real-life classroom: A new solid-state device can demonstrate the physical principles of invisibility cloaks without special equipment or magic spells April 30th, 2015

A phone with the ultimate macro feature: New attachment turns a smartphone into a microscope that can image and size DNA molecules 50,000 times thinner than a human hair April 29th, 2015

Arrowhead to Present at Upcoming Conferences April 28th, 2015

Nanobiotechnology

Artificial photosynthesis could help make fuels, plastics and medicine April 29th, 2015

A phone with the ultimate macro feature: New attachment turns a smartphone into a microscope that can image and size DNA molecules 50,000 times thinner than a human hair April 29th, 2015

An effective, biodegradable and broad-spectrum nanoparticles as potent antibacterial agents April 28th, 2015

Weighing -- and imaging -- molecules one at a time April 28th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project